Zealand Pharma — Maj 2025
-
Spørgsmål til Q&A d. 20/5 er stadig meget velkommen.
-
C25-regnskaber, 1. kvartal 2025: Karakterbogen https://proinvestor.com/boards/126363
-
Sundhedsaktierne i USA fortsatte nedturen - ikke længere sikker havn https://proinvestor.com/investornyt/1317372/sundhedsaktierne-i-usa-fortsatte-nedturen-ikke-laengere-sikker-havn
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1317380/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Pharma-aktier er typisk dem, investorer regner for en sikker havn i urolige tider. Men ikke engang dén sektor er fredet længere, hvor Trump kommer med udmeldinger om told og store prissænkninger på medicin i USA. Hvad kan vi som investorer se frem mod? Hvornår slutter dette mareridt? Det giver Helge Larsen sit bud på. Herudover omtales Lundbecks flotte regnskab og Genmabs udsigt til evt. lidt mindre royalty på Darzalex i 2029. https://proinvestor.com/boards/126377
-
****ZEALAND PHARMA/DEUTSCHE BANK: KURSMÅL SÆNKES TIL 485 KR. FRA 750 KR.
-
Zealand Pharma udpeger Steven Johnson som chef for udvikling https://proinvestor.com/investornyt/1318984/zealand-pharma-udpeger-steven-johnson-som-chef-for-udvikling
-
Q&A er afsluttet. Tusinde tak til alle for de skarpe spørgsmål.
-
Transcript fra Proinvestors Q&A med CEO Adam Steensberg fra Zealand Pharma tirsdag d. 20. maj 2025
Moderator: Redaktør Helge Larsen https://nbg1.your-objectstorage.com/proinvestor-dev/forum/ir/cms/QA-Zealand Pharma 2025-05-20.pdf -
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1319883/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Lilly’s former small molecule head makes the leap to a rising biotech in obesity
Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.
Yahoo Finance (finance.yahoo.com)
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1321060/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
****ZEALAND PHARMA/DANSKE BANK: GENOPTAGES MED "KØB"
-
Danske Bank: "We reinitiate coverage of Zealand Pharma with a 12M target price of DKK800 and a Buy recommendation. We base this on the value of Zealand’s obesity portfolio, which we find very promising, coupled with strong partnerships that increase the likelihood of a meaningful market presence."
-
Danske Bank: The Roche partnership, coupled with the share declining more than
50% from its peak in June 2024, causes us to find material upside potential in the
current share valuation and our 12M target price of DKK800. We identify upside
potential in our valuation to a share price of DKK1,350. -
tak
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind